Recent posts

TypePostAuthorRepliesLast updated
Page2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation Diane Singhroy036 weeks 4 days ago
Blog entryGates Foundation v. Teachscape: Restrictions on Patenting of Gates-Funded Inventions Andrew Goldman036 weeks 4 days ago
Blog entrySCP 24 - A fruitful discussion? Staff037 weeks 2 days ago
Book pageKEI Achievements Staff037 weeks 4 days ago
Blog entrySCP24: African Group submits revised proposal for a WIPO work program on Patents and Health thiru037 weeks 6 days ago
Blog entrySCP24: KEI statement on Patents and Health thiru038 weeks 3 days ago
Blog entryApril 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents KEI Staff038 weeks 3 days ago
PageWIPO SCCR 32 - links to KEI's reports from the meeting Manon Ress038 weeks 3 days ago
PageNews reports on Senator Hatch pressure over Colombia compulsory license on Novartis drug James Love038 weeks 3 days ago
Blog entryBriefing Call on National Institutes of Health (NIH) patent policies, 29 June 2016, 11:00 A.M. (EST) Zack Struver038 weeks 3 days ago
Blog entrySCP24: KEI statement on exceptions and limitations to patent rights thiru038 weeks 4 days ago
Blog entryStanding Committee on the Law of Patents (SCP) - GRULAC proposal - Revision of 1979 WIPO Model Law for Developing Countries thiru038 weeks 4 days ago
Blog entryColombia Issues Public Interest Declaration To Lower Price of Glivec KEI Staff039 weeks 2 days ago
Blog entryHuman Rights Council heats up during informal talks on the primacy of human rights over international trade and IP regimes thiru039 weeks 2 days ago
Blog entryS. Ward Casscells, Pentagon Medical Chief, Praised Army Role in Xtandi Development Zack Struver039 weeks 4 days ago
Blog entryUS Chamber of Commerce defends Swiss drug company charging excessive prices in Colombia James Love040 weeks 4 days ago
Blog entryNovartis complaints over public interest declaration debunked Andrew Goldman040 weeks 4 days ago
Blog entryWIPO IGC30: Questions remain on protection of genetic resources as hard decisions postponed until 2017 Staff040 weeks 4 days ago
Blog entryWHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO's work on R&D thiru040 weeks 4 days ago
Book pagePrizes to stimulate innovation James Love040 weeks 5 days ago
Blog entryObama administration blocking consensus at Human Rights Council on access to medicines resolution thiru040 weeks 6 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc. Diane Singhroy041 weeks 2 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to IntelliPanel Medical, LLC Diane Singhroy041 weeks 2 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation Diane Singhroy041 weeks 2 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc. Diane Singhroy041 weeks 2 days ago